2025

BioHarvest Launches Informed Sport-Certified VINIA DailyChews 2X Formula for Athletes and People with Active Lifestyles

Rehovot, Israel – June 4, 2025 – BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) (“BioHarvest” or the “Company”), a company pioneering its patented Botanical Synthesis technology platform, today announced the launch of VINIA® DailyChews 2X Formula, a first-of-its-kind chew designed to increase nitric oxide production and  arterial dilation, and to enhance blood flow and oxygen delivery for […]

BioHarvest Launches Informed Sport-Certified VINIA DailyChews 2X Formula for Athletes and People with Active Lifestyles Read More »

Cosmeceuticals

BioHarvest Secures New CDMO Contract to Develop Plant-based Fragrance Compound

First CDMO Project to Utilize In-house AI Tools for Discovery of Plant Cell Targets for the Botanical Synthesis Process Rehovot, Israel – May 21, 2025 – BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) (“BioHarvest” or the “Company”), a company pioneering its patented Botanical Synthesis technology platform, today announced that the Company’s Botanical Synthesis CDMO Services

BioHarvest Secures New CDMO Contract to Develop Plant-based Fragrance Compound Read More »

BioHarvest Sciences Reports First Quarter 2025 Financial Results

First Quarter Revenues Grew 47% to $7.9 Million, Exceeding Management Guidance Rehovot, Israel – May 15, 2025 – BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) (“BioHarvest” or the “Company”), a company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the first quarter ended March 31, 2025. First Quarter

BioHarvest Sciences Reports First Quarter 2025 Financial Results Read More »

BioHarvest Announces Completion of Stage 1 Development for CDMO Contract with Nasdaq-Listed Pharmaceutical Company

Successful Progression Validates Botanical Synthesis Platform for a Variety of Molecule Types Rehovot, Israel – May 12, 2025 – BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) (“BioHarvest” or the “Company”), a company pioneering its patented Botanical Synthesis technology platform, today announced that the Company’s previously announced CDMO contract with a Nasdaq-listed pharmaceutical company has progressed

BioHarvest Announces Completion of Stage 1 Development for CDMO Contract with Nasdaq-Listed Pharmaceutical Company Read More »

BioHarvest Sciences to Host First Quarter 2025 Earnings Call on May 15 at 4:30 p.m. Eastern Time

Rehovot, Israel – BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) (“BioHarvest” or the “Company”), a company pioneering its patented Botanical Synthesis technology platform, today announced that it will release financial results for the first quarter ended March 31, 2025 after market close on Thursday, May 15, 2025. Management will host an investor conference call and

BioHarvest Sciences to Host First Quarter 2025 Earnings Call on May 15 at 4:30 p.m. Eastern Time Read More »

Vinia

BioHarvest Sciences Reports Fourth Quarter and Full Year 2024 Financial Results

Fourth Quarter Revenues Grew 62% to $7.3 Million, Exceeding Prior Management Guidance, with Full Year Revenues Increasing 99% Year-Over-Year to $25.2 Million CDMO Division Secures Anchor Partnership with Tate & Lyle to Develop Next Generation of Plant-Based Sweeteners Rehovot, Israel – March 31, 2025 – BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) (“BioHarvest” or the

BioHarvest Sciences Reports Fourth Quarter and Full Year 2024 Financial Results Read More »